X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7640) 7640
Publication (1357) 1357
Book Review (1200) 1200
Conference Proceeding (34) 34
Magazine Article (27) 27
Book / eBook (17) 17
Trade Publication Article (11) 11
Web Resource (9) 9
Book Chapter (8) 8
Data Set (7) 7
Dissertation (3) 3
Government Document (2) 2
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7464) 7464
index medicus (7084) 7084
anti-retroviral agents - therapeutic use (6864) 6864
hiv infections - drug therapy (5812) 5812
female (4455) 4455
male (4286) 4286
adult (3774) 3774
hiv (3504) 3504
infectious diseases (2877) 2877
middle aged (2488) 2488
antiretroviral therapy (2273) 2273
human immunodeficiency virus--hiv (2161) 2161
immunology (1927) 1927
antiretroviral drugs (1588) 1588
aids/hiv (1546) 1546
aids (1545) 1545
antiviral agents (1498) 1498
hiv infection (1357) 1357
drug therapy (1294) 1294
hiv infections - epidemiology (1288) 1288
viral load (1254) 1254
hiv infections - complications (1249) 1249
adolescent (1180) 1180
cd4 lymphocyte count (1174) 1174
young adult (1172) 1172
highly active antiretroviral therapy (1123) 1123
virology (1100) 1100
risk factors (1076) 1076
treatment outcome (1048) 1048
hiv infections - virology (1016) 1016
public, environmental & occupational health (987) 987
health aspects (965) 965
acquired immune deficiency syndrome--aids (958) 958
therapy (883) 883
human-immunodeficiency-virus (832) 832
hiv infections - immunology (828) 828
article (826) 826
research (813) 813
mortality (810) 810
hiv infections - prevention & control (764) 764
medicine, general & internal (761) 761
anti-retroviral agents - adverse effects (757) 757
prevalence (750) 750
hiv/aids (741) 741
infection (732) 732
cohort studies (727) 727
abridged index medicus (702) 702
care and treatment (700) 700
aged (699) 699
cross-sectional studies (696) 696
child (667) 667
prevention (659) 659
hiv patients (651) 651
hiv-1 (640) 640
active antiretroviral therapy (636) 636
analysis (632) 632
pregnancy (632) 632
human immunodeficiency virus (631) 631
hiv infections - transmission (625) 625
retrospective studies (618) 618
antiretroviral therapy, highly active (605) 605
microbiology (605) 605
hiv infections - diagnosis (593) 593
antiretroviral agents (585) 585
adherence (575) 575
research article (568) 568
hiv infections - psychology (548) 548
acquired immunodeficiency syndrome - drug therapy (537) 537
prospective studies (537) 537
anti-retroviral agents - administration & dosage (511) 511
medicine (502) 502
infant (475) 475
medication adherence (475) 475
pharmacology & pharmacy (460) 460
anti-retroviral agents - pharmacology (459) 459
public health (459) 459
risk (459) 459
child, preschool (456) 456
infections (446) 446
virus diseases (438) 438
adults (433) 433
drug therapy, combination (433) 433
time factors (432) 432
patients (428) 428
hiv infections - mortality (422) 422
africa (417) 417
patient compliance (406) 406
tuberculosis (406) 406
hiv-1 - drug effects (400) 400
hiv-1 - genetics (399) 399
usage (397) 397
children (396) 396
acquired immune deficiency syndrome (394) 394
anti-hiv agents - therapeutic use (392) 392
infected patients (385) 385
antiretroviral therapy, highly active - methods (383) 383
south-africa (383) 383
disease progression (381) 381
dosage and administration (381) 381
social sciences, biomedical (376) 376
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7288) 7288
French (164) 164
Spanish (109) 109
German (36) 36
Chinese (30) 30
Portuguese (22) 22
Japanese (13) 13
Russian (11) 11
Dutch (10) 10
Italian (6) 6
Polish (4) 4
Czech (3) 3
Danish (3) 3
Turkish (3) 3
Serbian (2) 2
Hungarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 705 - 713
Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and... 
MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | INTERFERON | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | ALPHA-2A PLUS RIBAVIRIN | VETERANS | GENOTYPE 1 INFECTION | COHORT | LIVER-DISEASE | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
by Danel, Christine and Moh, Raoul and Gabillard, Delphine and Badje, Anani and Le Carrou, Jérôme and Ouassa, Timothée and Ouattara, Eric and Anzian, Amani and Ntakpé, Jean-Baptiste and Minga, Albert and Kouame, Gérard M and Bouhoussou, Franck and Emieme, Arlette and Kouamé, Antoine and Inwoley, André and Toni, Thomas-D'Aquin and Ahiboh, Hugues and Kabran, Mathieu and Rabe, Cyprien and Sidibé, Baba and Nzunetu, Gustave and Konan, Romuald and Gnokoro, Joachim and Gouesse, Patrice and Messou, Eugène and Dohoun, Lambert and Kamagate, Synali and Yao, Abo and Amon, Solange and Kouame, Amadou-Barenson and Koua, Aboli and Kouamé, Emmanuel and Ndri, Yao and Ba-Gomis, Olivier and Daligou, Marcelle and Ackoundzé, Simplice and Hawerlander, Denise and Ani, Alex and Dembéle, Fassery and Koné, Fatoumata and Guéhi, Calixte and Kanga, Constance and Koule, Serge and Séri, Jonas and Oyebi, Mykayila and Mbakop, Nathalie and Makaila, Olewole and Babatunde, Carole and Babatounde, Nathanael and Bleoué, Gisèle and Tchoutedjem, Mireille and Kouadio, Alain-Claude and Sena, Ghislaine and Yededji, Sahinou-Yediga and Assi, Rodrigue and Bakayoko, Alima and Mahassadi, Alassane and Attia, Alain and Oussou, Armel and Mobio, Max and Bamba, Doféré and Koman, Mesmin and Horo, Apollinaire and Deschamps, Nina and Chenal, Henri and Sassan-Morokro, Madeleine and Konate, Seidou and Aka, Kakou and Aoussi, Eba and Journot, Valérie and Nchot, Célestin and Karcher, Sophie and Chaix, Marie-Laure and Rouzioux, Christine and Sow, Papa-Salif and Perronne, Christian and Girard, Pierre-Marie and Menan, Hervé and Bissagnene, Emmanuel and Kadio, Auguste and Ettiegne-Traore, Virginie and Moh-Semdé, Corinne and Kouame, Abo and Massumbuko, Jean-Marie and Chêne, Geneviève and Dosso, Mireille and Domoua, Serge K and N'Dri-Yoman, Thérèse and Salamon, Roger and Eholié, Serge P and Anglaret, Xavier and The TEMPRANO ANRS 12136 Study Group and TEMPRANO ANRS 12136 Study Group
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 808 - 822
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2110 - 2118
In HIV-infected Ugandan children, lopinavir–ritonavir–based ART was associated with a decreased incidence of malaria, as compared with ART based on an NNRTI,... 
TYPE-1 PROTEASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | IN-VITRO | THERAPY | PLASMODIUM-FALCIPARUM | ARTEMETHER-LUMEFANTRINE | DRUGS | ANTIMALARIAL ACTIVITY | EXPOSURE | Artemisinins - pharmacokinetics | Humans | Fluorenes - therapeutic use | Child, Preschool | Infant | Male | Secondary Prevention | Incidence | Ethanolamines - pharmacokinetics | Drug Interactions | Malaria - epidemiology | Ritonavir - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Fluorenes - pharmacokinetics | Anti-Retroviral Agents - therapeutic use | Antimalarials - pharmacokinetics | Kaplan-Meier Estimate | Antimalarials - therapeutic use | HIV Protease Inhibitors - therapeutic use | Malaria - prevention & control | Artemisinins - therapeutic use | Ethanolamines - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Uganda | Malaria - drug therapy | Drug Combinations | Malaria | Patient outcomes | HIV infection in children | Research | Risk factors | Prevention | Complications and side effects | Highly active antiretroviral therapy | Reverse transcriptase inhibitors | Dosage and administration | Comparative analysis | Drug therapy | Health aspects | Antiretroviral drugs | Alanine | Ritonavir | Lopinavir | Insecticides | Proteinase inhibitors | Pruritus | Antiretroviral therapy | Antiretroviral agents | Human immunodeficiency virus--HIV | Alanine transaminase | Artemether | Children | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 5, pp. 423 - 434
In this study, 1219 HIV-uninfected, heterosexual adults in Botswana were randomly assigned to tenofovir–emtricitabine (TDF–FTC) or placebo. The TDF–FTC group... 
PREVENTION | TRIALS | MEDICINE, GENERAL & INTERNAL | TENOFOVIR DISOPROXIL FUMARATE | INFECTION | EMTRICITABINE | HIV Infections - prevention & control | Humans | Drug Resistance, Viral | Male | RNA, Viral - blood | Viral Load | Tenofovir | Young Adult | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | HIV-2 - genetics | Contraception Behavior - statistics & numerical data | Drug Therapy, Combination | Emtricitabine | Anti-Retroviral Agents - therapeutic use | Adenine - analogs & derivatives | HIV Seropositivity | Organophosphonates - therapeutic use | HIV-2 - isolation & purification | Anti-Retroviral Agents - adverse effects | Kaplan-Meier Estimate | Organophosphonates - adverse effects | Proportional Hazards Models | Sexual Behavior - statistics & numerical data | HIV-1 - genetics | Bone Density - drug effects | Adolescent | Deoxycytidine - analogs & derivatives | Prevention | Drugs | Dose-response relationship (Biochemistry) | Control | Disease transmission | Dosage and administration | Product/Service Evaluations | Drug therapy | HIV infection | Medical research | Prophylaxis | Infections | Nausea | Disease control | Studies | Motivation | Antiretroviral agents | Vomiting | Human immunodeficiency virus--HIV | Bone mineral density | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2012, Volume 12, Issue 1, pp. 27 - 35
Summary Background Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir... 
Infectious Disease | INFECTIOUS DISEASES | DARUNAVIR-RITONAVIR | TREATMENT-NAIVE | DOSE-RESPONSE | COMBINATION THERAPY | TMC125 ETRAVIRINE | HIV-1-INFECTED PATIENTS | INFECTION | PLACEBO-CONTROLLED TRIAL | INTEGRASE INHIBITOR | SUBGROUP | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Diarrhea - chemically induced | Viral Load | Oligopeptides - therapeutic use | Pyrrolidinones - administration & dosage | HIV Infections - immunology | Drug Therapy, Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Female | Raltegravir Potassium | Pyridines - therapeutic use | Anti-Retroviral Agents - therapeutic use | Pyrrolidinones - adverse effects | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Pyrrolidinones - therapeutic use | Treatment Outcome | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | HIV-1 - immunology | Quinolones - administration & dosage | Aspartate Aminotransferases - blood | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Lopinavir - therapeutic use | Antiviral agents | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | HIV patients | HIV (Viruses) | Anti-HIV agents | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 714 - 725
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article